Keros Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Keros Therapeutics, Inc. (KROS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-09.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2022-03-09
- Keros Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-12-31 was $0.00.
- Keros Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-09-30 was $0.00.
- Keros Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-06-30 was $0.00.
- Keros Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-03-31 was $0.00.
- Keros Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $0.00.
- Keros Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was -$1.49M.
- Keros Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2019 was -$2.56M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $0.00 derived: sum of 2 quarters · filed 2022-03-09 | $0.00 derived: sum of 3 quarters · filed 2022-03-09 | $0.00 10-K · filed 2022-03-09 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2022-03-09 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | $0.00 derived: sum of 3 quarters · filed 2022-03-09 | $0.00 derived: sum of 4 quarters · filed 2022-03-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2022-03-09 | $0.00 derived: sum of 3 quarters · filed 2022-03-09 | $0.00 derived: sum of 4 quarters · filed 2022-03-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $0.00 derived: sum of 2 quarters · filed 2022-03-09 | $0.00 derived: sum of 3 quarters · filed 2022-03-09 | -$1.49M 10-K · filed 2022-03-09 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | -$1.49M 10-Q · filed 2021-11-04 | -$1.57M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | -$1.49M 10-Q · filed 2021-08-05 | -$1.57M derived: sum of 3 quarters · filed 2021-08-05 | -$2.80M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$1.49M 10-Q · filed 2021-05-06 | -$1.57M derived: sum of 2 quarters · filed 2021-05-06 | -$2.80M derived: sum of 3 quarters · filed 2021-05-06 | -$3.45M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$1.31M derived: sum of 2 quarters · filed 2021-03-25 | -$1.96M derived: sum of 3 quarters · filed 2021-03-25 | -$2.56M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$1.24M 10-Q · filed 2020-11-10 | -$1.88M derived: sum of 2 quarters · filed 2020-11-10 | -$2.49M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$647.00K 10-Q · filed 2020-08-13 | -$1.25M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$604.00K 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |